Skip to content
ChickenStockChickenStock
ResearchPACB
Pacific Biosciences California logo

Pacific Biosciences California (PACB) stock

NASDAQ

$1.96-0.51%(-0.01)

As of the Nov 13, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-4.68x

Net loss — not comparable

P/B

—

P/S

3.78x

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Revenue increased 7.9% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 5, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

4 SEC filings
  • Gibson James R IISee Remarks · Oct 6, 2026Open-market sale661,815 shares · $2.1M
    Avg. price $3.1081,083,848 shares held after
  • Gibson James R IISee Remarks · Oct 6, 2026Option exercise500,000 shares · $590K
    Avg. price $1.181,745,663 shares held after
  • Van Oene MarkSee Remarks · Aug 17, 2026Open-market sale26,911 shares · $30K
    Avg. price $1.132,705,853 shares held after
  • Van Oene MarkSee Remarks · Aug 10, 2026Grant or award489,130 shares · $0
    Avg. price $02,732,764 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Pacific Biosciences California (PACB) stock information

NASDAQ

Pacific Biosciences California (PACB) is listed on NASDAQ. Its market capitalization is about $613M. On trailing-twelve-month earnings the P/E ratio is -4.68. These figures are computed in-house from official filings and are reference information only.

Pacific Biosciences California — frequently asked questions

What is the P/E ratio of Pacific Biosciences California (PACB)?
On a trailing-twelve-month basis, PACB trades at a P/E ratio of -4.68. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Pacific Biosciences California?
PACB has a market capitalization of about $613M. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.